Full-Time

Lead Environmental

Health, Safety, And Sustainability, EHSS Engineer

Updated on 8/1/2026

United Therapeutics Corporation

United Therapeutics Corporation

Biotech company develops PAH therapies

Compensation Overview

$105.5k - $150k/yr

Durham, NC, USA + 1 more

More locations: Silver Spring, MD, USA

In Person

On-site 100% of the time; may require up to 10% travel to other company locations, conferences, or training.

Category
Lab & Research (1)
Required Skills
OSHA

Get referred to United Therapeutics Corporation

See people who can refer or advise you

Requirements
  • A bachelor's degree in occupational health and safety, engineering, or environmental engineering is required.
  • A minimum of 8+ years of relevant work experience in pharma, life sciences, or chemical engineering is required.
  • At least 6 years of Environmental, Health, Safety, and Sustainability experience in high-level expansion projects is required.
  • A proven track record of successful interaction with personnel from multiple regulatory agencies is required.
  • Experience auditing Environmental, Health, Safety, and Sustainability management systems is required.
  • Project management skills with attention to detail, timelines, and results are required.
  • The ability to develop and sustain a strong Environmental, Health, and Safety culture is required.
  • Integrity and alignment with the Environmental, Health, and Safety mission and values are required.
Responsibilities
  • Establish and maintain Environmental, Health, Safety, and Sustainability-focused corporate social responsibility management systems that align with United Therapeutics' mission and values.
  • Support business growth by engineering designs and assessing new projects and processes for Environmental, Health, Safety, and Sustainability impact, including participation in owner, architect, and contractor meetings.
  • Apply technical expertise in environmental compliance and stewardship, including air, water, hazardous waste, materials management, and chemical reporting; support program implementation across the corporation and drive continuous improvement and sustainability practices.
  • Apply technical expertise in product stewardship, qualitative occupational exposure assessments, and high-potent compound safety.
  • Apply technical expertise in health and safety compliance, including injury and illness prevention, materials handling, energy control, biosafety, radiation safety, laboratory safety, personal protective equipment assessments, occupational health, fall protection, and emergency preparedness.
  • Oversee site water use and discharge control programs, including permit writing, agency notifications, monitoring requirements, periodic sampling, user reports, and records retention.
  • Oversee site waste management, including pollution prevention, chemical and biological waste removal, waste profiles, maintaining manifests, conducting inspections, environmental reporting, and records retention.
  • Complete chemical reporting and community right-to-know submissions; maintain electronic chemical inventory records and safety data sheets; and identify materials on Environmental Protection Agency or Occupational Safety and Health Administration lists.
  • Develop engineering controls for biological, high-potent compound, chemical, energy, flammable-liquid, and fall-protection hazards.
  • Develop and implement temporary-worker and contractor safety protocols.
Desired Qualifications
  • Pharma or life sciences experience is strongly preferred.
  • Certified Safety Professional or Certified Industrial Hygienist certification is preferred.
  • Experience in an FDA-regulated environment is preferred.
United Therapeutics Corporation

United Therapeutics Corporation

View

United Therapeutics develops therapies for life-threatening diseases, with a focus on pulmonary arterial hypertension and rare conditions. Its approved medicines, including Remodulin, Tyvaso, Orenitram, Adcirca, and Unituxin, treat PAH and pediatric neuroblastoma and are delivered by injections, inhalations, or oral tablets. The company also pursues regenerative medicine and xenotransplantation through its Lung Biotechnology PBC and Revivicor units to create bioengineered organs for transplant. It differentiates itself by combining drug development with organ engineering and by operating as a Public Benefit Corporation that balances profits with social and environmental goals, aiming to extend lives and increase access to transplantable organs.

Company Size

N/A

Company Stage

IPO

Headquarters

Durham, North Carolina

Founded

1996

Get referred to United Therapeutics Corporation

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • LungFX FDA approval enables 2027 launch of ex vivo lung perfusion services, expanding donor lung utilization beyond 20%.
  • Thymmune acquisition adds iPSC-based thymic therapies targeting transplant tolerance and congenital athymia through 2031 milestones.
  • Varda Space partnership targets microgravity drug crystallization for improved pulmonary drug stability and bioavailability by early 2027.

What critics are saying

  • Xenotransplantation faces FDA safety backlash from zoonotic virus or rejection risks, halting UThymoKidney and LungFX trials by 2028.
  • Varda Space fails to scale due to reentry failures or launch delays, causing loss of microgravity R&D partner and missing 2030 trials.
  • Positive nebulized Tyvaso data fails FDA approval due to competitor drugs like Boehringer Ingelheim's Upadacitinib or Medicare pricing pressure.

What makes United Therapeutics Corporation unique

  • Dominates PAH market with Tyvaso generating $1.62B in 2024, outpacing Johnson & Johnson and Liquidia competitors.
  • First publicly traded biotech organized as a Public Benefit Corporation since 2021, balancing profit with patient mission.
  • Pioneers organ manufacturing via xenotransplantation, 3D bioprinting, and ex vivo lung perfusion to eliminate transplant shortages.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

401(k) Retirement Plan

401(k) Company Match

Paid Time Off

Paid Holidays

Paid Vacation

Parental Leave

Family Planning Benefits

Fertility Treatment Support

Adoption Assistance

Childcare Support

Elder Care Support

Wellness Program

Mental Health Support

Gym Membership

Phone/Internet Stipend

Home Office Stipend

Conference Attendance Budget

Professional Development Budget

Professional Certification Support

Tuition Reimbursement

Stock Options

Company Equity

Employee Stock Purchase Plan

Relocation Assistance

Employee Referral Bonus

Performance Bonus

Profit Sharing

Sabbatical Leave

Hybrid Work Options

Remote Work Options

Flexible Work Hours

ParentAL Leave

Company News

Domestic Cleaning Business Network
Jul 2nd, 2026
United Therapeutics buys Massachusetts biotech Thymmune Therapeutics for $140M

United Therapeutics buys Massachusetts biotech Thymmune Therapeutics for $140M July 2, 2026 DCBN News, Syndication Comments Off on United Therapeutics buys Massachusetts biotech Thymmune Therapeutics for $140M

Yahoo Finance
Mar 19th, 2026
The Trade Desk and United Therapeutics emerge as mid-cap growth picks while Builders FirstSource stumbles

Here is a summary of the article: Investment analysis platform StockStory has identified two mid-cap stocks worth buying and one to avoid. The Trade Desk, a cloud-based advertising platform, trades at $23.53 per share with a market capitalisation of $11.21 billion. The company posted 22% annual revenue growth over the past two years and boasts a 20.3% operating margin. United Therapeutics, which develops treatments for chronic lung diseases, has a market capitalisation of $23.24 billion. The company achieved 16.9% annual revenue growth over two years whilst demonstrating strong free cash flow generation and improving returns on capital. StockStory advises avoiding Builders FirstSource, a construction materials manufacturer. The company experienced 5.7% annual sales declines over the past two years, with eroding returns on capital and declining earnings per share.

Yahoo Finance
Mar 14th, 2026
United Therapeutics publishes Tyvaso IPF data in NEJM, eyes first inhaled anti-fibrotic approval

United Therapeutics has published full Phase 3 TETON-2 trial data for nebulised Tyvaso in idiopathic pulmonary fibrosis in the New England Journal of Medicine. The study demonstrated preservation of lung function and reduced clinical worsening in IPF patients. If approved by the FDA, Tyvaso would become the first and only inhaled anti-fibrotic treatment for IPF, significantly expanding United Therapeutics' addressable market. The company's shares currently trade at $536.12, with one-year returns of 74.5%. The publication in a top-tier journal represents a significant milestone for the drug developer. Investors are now monitoring potential FDA review milestones and how IPF could influence revenue beyond the current $3.2 billion base, though regulatory or reimbursement challenges remain key risks.

Yahoo Finance
Feb 26th, 2026
United Therapeutics shares drop 7.2% on $790M revenue miss despite earnings beat

United Therapeutics shares fell 7.2% after the biotechnology company reported fourth-quarter revenue of $790.2 million, missing analysts' consensus estimates of over $805 million. Whilst revenue grew 7% year-over-year, Tyvaso sales, though up 12%, also fell short of projections. The company did beat earnings expectations with adjusted earnings of $7.70 per share versus the forecasted $7.10. However, the revenue miss overshadowed the earnings beat, prompting negative market reaction. The stock has shown relatively low volatility over the past year, with only eight moves greater than 5%. United Therapeutics is currently trading at $500.08 per share, near its 52-week high of $535.10. Shares are flat year-to-date.

Yahoo Finance
Feb 26th, 2026
United Therapeutics targets 2026 soft-mist inhaler launch, surpasses $3B in annual revenue

United Therapeutics reported fourth-quarter 2025 results, with full-year revenue surpassing $3 billion for the first time, representing 11% growth. Fourth-quarter revenue reached $790 million, whilst Tyvaso generated $464 million with dry-powder inhaler sales growing 24% year-over-year. The company plans to file its soft-mist treprostinil inhaler, Tresmi, for approval this year, targeting a 2026 commercial launch. Early studies suggest the device could reduce coughing by up to 90% compared to dry-powder alternatives. Near-term catalysts include a once-daily "super prostacyclin" readout next week and TETON-1 IPF trial results next month, with potential launch by June 2027. The company's Zeno xenotransplant programme has transplanted two patients, targeting a commercial product by 2030.